BL Pharmtech Statistics

Total Valuation

BL Pharmtech has a market cap or net worth of KRW 26.82 billion. The enterprise value is 29.07 billion.

Market Cap	26.82B
Enterprise Value	29.07B

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

BL Pharmtech has 26.68 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	26.68M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	27.53%
Owned by Institutions (%)	n/a
Float	19.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.05
PB Ratio	1.10
P/TBV Ratio	1.12
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.09
EV / Sales	3.30
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-6.92

Financial Position

The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.25.

Current Ratio	1.05
Quick Ratio	0.73
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	-1.45
Interest Coverage	-5.24

Financial Efficiency

Return on equity (ROE) is -20.39% and return on invested capital (ROIC) is -8.18%.

Return on Equity (ROE)	-20.39%
Return on Assets (ROA)	-6.68%
Return on Invested Capital (ROIC)	-8.18%
Return on Capital Employed (ROCE)	-14.56%
Revenue Per Employee	628.97M
Profits Per Employee	-407.60M
Employee Count	14
Asset Turnover	0.22
Inventory Turnover	1.64

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -37.71% in the last 52 weeks. The beta is 0.88, so BL Pharmtech's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	-37.71%
50-Day Moving Average	1,262.25
200-Day Moving Average	1,262.49
Relative Strength Index (RSI)	42.46
Average Volume (20 Days)	332,208

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BL Pharmtech had revenue of KRW 8.81 billion and -5.71 billion in losses. Loss per share was -213.80.

Revenue	8.81B
Gross Profit	5.92B
Operating Income	-4.34B
Pretax Income	-5.77B
Net Income	-5.71B
EBITDA	-3.49B
EBIT	-4.34B
Loss Per Share	-213.80

Full Income Statement

Balance Sheet

The company has 3.86 billion in cash and 6.10 billion in debt, giving a net cash position of -2.24 billion or -83.80 per share.

Cash & Cash Equivalents	3.86B
Total Debt	6.10B
Net Cash	-2.24B
Net Cash Per Share	-83.80
Equity (Book Value)	24.27B
Book Value Per Share	9,086.00
Working Capital	308.53M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.04 billion and capital expenditures -1.17 billion, giving a free cash flow of -4.20 billion.

Operating Cash Flow	-3.04B
Capital Expenditures	-1.17B
Free Cash Flow	-4.20B
FCF Per Share	-157.54

Full Cash Flow Statement

Margins

Gross margin is 67.24%, with operating and profit margins of -49.34% and -64.81%.

Gross Margin	67.24%
Operating Margin	-49.34%
Pretax Margin	-65.48%
Profit Margin	-64.81%
EBITDA Margin	-39.66%
EBIT Margin	-49.34%
FCF Margin	n/a

Dividends & Yields

BL Pharmtech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-21.28%
FCF Yield	-15.68%

Stock Splits

The last stock split was on February 26, 2025. It was a forward split with a ratio of 3.

Last Split Date	Feb 26, 2025
Split Type	Forward
Split Ratio	3

Scores

BL Pharmtech has an Altman Z-Score of -0.89. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.89
Piotroski F-Score	n/a